Cargando…
Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report
BACKGROUND: Diffuse alveolar bleeding is a potentially life-threatening condition that can be induced by several drugs. Whereas fatal cases have been reported in patients treated for other indications, no report have so far been published in a patient with multiple sclerosis treated with alemtuzumab...
Autores principales: | Myro, Aija Zuleron, Bjerke, Gisle, Zarnovicky, Svetozar, Holmøy, Trygve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245888/ https://www.ncbi.nlm.nih.gov/pubmed/30454022 http://dx.doi.org/10.1186/s40360-018-0267-5 |
Ejemplares similares
-
Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber’s optic neuropathy and multiple sclerosis – a case report
por: Holmøy, Trygve, et al.
Publicado: (2016) -
Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab
por: Holmøy, Trygve, et al.
Publicado: (2018) -
Progressive encephalomyelitis with rigidity and myoclonus (PERM) associated with anti-glycine receptor antibodies and urothelial carcinoma: a case report
por: Ali, Amanuel Hassen, et al.
Publicado: (2023) -
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019) -
ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)